Product Data Sheet

D-erythro-Sphingosine-d₇

Cat. No.:	HY-101047S	
CAS No.:	1246304-34-6	
Molecular Formula:	$C_{18}H_{30}D_{7}NO_{2}$	
Molecular Weight:	306.54	
Target:	PKC; Endogenous Metabolite; Phosphatase	
Pathway:	Epigenetics; TGF-beta/Smad; Metabolic Enzyme/Protease	
Storage:	Powder -20°C 3 years	
	In solvent -80°C 6 months	
	-20°C 1 month	

BIOLOGICAL ACTIVITY		
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 (Pt 3):699-703.

[3]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91.

[4]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7.

[5]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fa

Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA